Skip to content

PSX Pharmaceuticals

BFBIO BF Biosciences Limited

Latest results: FY2026 · Jun 2026

Last close · 13 Nov 2026

Rs 135.26 ▼ 1.13 (-0.83%)

▼ 10.8% 1 year

15 Oct 22 Oct 28 Oct 3 Nov 11 Nov Jun Jul Aug Sep Oct Dec Feb May Jul Oct 2024 2025 2025 2026 2026
117.2052-week range177.99
Market cap
—
P/E
—
FY2026
P/B
—
FY2026
Dividend yield
—
FY2026
ROE
12.7%
FY2026
Sector 21.7% · lower
EPS
—
FY2026
Book value / share
—
FY2026

Price performance

BFBIO returns

Close Rs 135.26
13 Nov 2026

Period Return Rs
MTD +7.1% +0.2 pts vs KSE +8.99
3M +0.0% +1.3 pts vs KSE +0.01
6M −0.5% −6.8 pts vs KSE −0.72
YTD −3.7% −5.9 pts vs KSE −5.26
FYTD −5.3% −4.0 pts vs KSE −7.62
1Y −10.8% −21.6 pts vs KSE −16.45

Price return from the last close before each period; the fiscal year ends 30 June. Dividends are not included.

BF Biosciences Limited in brief

Return on equity was 12.7%.

Scorecard vs Pharmaceuticals

14 companies
Growth
No figure
—
Profitability
No figure
—
Financial health
No figure
—
Valuation
No figure
—
Dividends
No figure
—

Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.

Corporate

BFBIO announcements & payouts

All BFBIO announcements →
28 Oct 2026 · 11:43
Result · First quarter to 30 Sep 2026
Profit after tax
Rs 184.9 mn
EPS
Rs 2.09 +15.5%
EPS a year earlier
Rs 1.81
29 Sep 2026 · 12:44
Result · Full year to 30 Jun 2026 AGM 28 Oct
Profit after tax
Rs 632.1 mn
EPS
Rs 7.16 +29.7%
EPS a year earlier
Rs 5.52

Book closure 21 Oct – 28 Oct 2026

28 Apr 2026 · 14:48
Result · Nine months to 31 Mar 2026
Profit after tax
Rs 464.9 mn
EPS
Rs 5.26 +28.9%
EPS a year earlier
Rs 4.08
4 Mar 2026 · 12:03
Result · Half year to 31 Dec 2025
Profit after tax
Rs 347.3 mn
EPS
Rs 3.93 +47.7%
EPS a year earlier
Rs 2.66

Financial highlights

BFBIO financial results

BFBIO annual financial highlights (Rs mn)
Rs mn FY2026 Jul 2025 – Jun 2026 FY2025 Jul 2024 – Jun 2025 FY2024 Jul 2023 – Jun 2024 FY2023 Jul 2022 – Jun 2023 FY2022 Jul 2021 – Jun 2022 FY2021 Jul 2020 – Jun 2021 FY2020 Jul 2019 – Jun 2020
Revenue — 5,837.5 3,658.7 1,809.5 1,520.7 1,754.8 628.3
Gross profit — 2,286.1 1,532.0 449.0 457.8 796.5 86.5
Operating profit 1,089.4 735.4 711.7 270.3 246.9 610.2 21.2
Profit after tax — 447.1 385.4 149.1 307.0 608.0 47.1
Profit attributable to shareholders — 447.1 385.4 149.1 307.0 608.0 47.1
EPS – basic (Rs) Rs — 5.52 4.36 1.69 3.48 6.88 0.53
Dividend per share (Rs) Rs — 0.00 0.00 0.00 0.00 0.00 0.00
Total assets — 8,158.5 5,860.0 5,666.8 4,435.1 2,994.8 1,047.7
Total equity — 4,662.0 2,359.6 1,974.2 1,825.2 1,466.6 782.4
Total debt — 1,724.8 2,212.3 2,602.7 1,744.1 889.4 6.4
Net cash from operating activities — 282.6 519.5 (232.9) 292.0 583.7 (12.0)
Capital expenditure — (329.5) (143.1) (1,970.0) (1,130.2) (941.1) (22.2)
Free cash flow (operating cash flow − capex) — (46.9) 376.4 (2,203.0) (838.1) (357.4) (34.2)
BFBIO quarterly financial highlights (Rs bn)
Rs bn TTM to Jun 2026 Q4 FY2026 Apr – Jun 2026 Q3 FY2026 Jan – Mar 2026 Q2 FY2026 Oct – Dec 2025 Q1 FY2026 Jul – Sep 2025 Q4 FY2025 Apr – Jun 2025 Q3 FY2025 Jan – Mar 2025 Q2 FY2025 Oct – Dec 2024 Q1 FY2025 Jul – Sep 2024
Revenue — — 2.1 2.7 2.4 1.6 1.5 1.3 1.4
Gross profit — — 1.0 1.2 1.0 0.6 0.5 0.6 0.6
Operating profit — — 0.2 0.4 0.3 0.2 0.2 0.2 0.2
Profit after tax — — 0.1 0.2 0.2 0.1 0.1 0.1 0.1
Profit attributable to shareholders — — 0.1 0.2 0.2 0.1 0.1 0.1 0.1
EPS – basic (Rs) Rs — — 1.33 2.13 1.81 1.44 1.59 1.37 1.30
Dividend per share (Rs) Rs — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total assets — — 9.2 10.0 8.7 8.2 8.2 8.4 8.2
Total equity — — 5.1 5.0 4.8 4.7 4.5 4.4 2.5
Total debt — — 1.7 1.6 1.8 1.7 1.9 2.1 2.3
Net cash from operating activities — — (0.8) 0.6 0.0 0.5 (0.4) 0.2 0.0
Capital expenditure — — (0.1) (0.2) (0.1) (0.1) (0.0) (0.1) (0.1)
Free cash flow (operating cash flow − capex) — — (1.0) 0.4 (0.0) 0.4 (0.4) 0.1 (0.1)

Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.

BFBIO charts

Revenue and profit Revenue Profit attributable
Revenue and profit Rs 6 bn Revenue FY20: Rs 628.3 mn Profit attributable FY20: Rs 47.1 mn FY20 Revenue FY21: Rs 1.8 bn Profit attributable FY21: Rs 608.0 mn FY21 Revenue FY22: Rs 1.5 bn Profit attributable FY22: Rs 307.0 mn FY22 Revenue FY23: Rs 1.8 bn Profit attributable FY23: Rs 149.1 mn FY23 Revenue FY24: Rs 3.7 bn Profit attributable FY24: Rs 385.4 mn FY24 Revenue FY25: Rs 5.8 bn Profit attributable FY25: Rs 447.1 mn FY25 FY26
Margins Gross margin Operating margin Net margin
Margins 49% 25% 0% Gross margin FY20: 13.8% Gross margin FY21: 45.4% Gross margin FY22: 30.1% Gross margin FY23: 24.8% Gross margin FY24: 41.9% Gross margin FY25: 39.2% Operating margin FY20: 3.4% Operating margin FY21: 34.8% Operating margin FY22: 16.2% Operating margin FY23: 14.9% Operating margin FY24: 19.5% Operating margin FY25: 12.6% Net margin FY20: 7.5% Net margin FY21: 34.6% Net margin FY22: 20.2% Net margin FY23: 8.2% Net margin FY24: 10.5% Net margin FY25: 7.7% FY20 FY21 FY22 FY23 FY24 FY25 FY26
Cash flow Operating cash flow Capex Free cash flow
Cash flow Rs 584 mn -Rs 2 bn Operating cash flow FY20: -Rs 12.0 mn Capex FY20: -Rs 22.2 mn Free cash flow FY20: -Rs 34.2 mn FY20 Operating cash flow FY21: Rs 583.7 mn Capex FY21: -Rs 941.1 mn Free cash flow FY21: -Rs 357.4 mn FY21 Operating cash flow FY22: Rs 292.0 mn Capex FY22: -Rs 1.1 bn Free cash flow FY22: -Rs 838.1 mn FY22 Operating cash flow FY23: -Rs 232.9 mn Capex FY23: -Rs 2.0 bn Free cash flow FY23: -Rs 2.2 bn FY23 Operating cash flow FY24: Rs 519.5 mn Capex FY24: -Rs 143.1 mn Free cash flow FY24: Rs 376.4 mn FY24 Operating cash flow FY25: Rs 282.6 mn Capex FY25: -Rs 329.5 mn Free cash flow FY25: -Rs 46.9 mn FY25 FY26

Valuation

BFBIO valuation at today's price

Price to earnings (P/E)
—
EPS — (FY2026)
Price to book (P/B)
—
Book value — (FY2026)
Dividend yield
—
DPS — (FY2026)
Earnings yield
—
EPS ÷ price

At the closing price of Rs 135.26 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.

Sector peers

BFBIO vs Pharmaceuticals companies

Largest companies in the sector at today's prices
Company Market cap P/E P/B Yield ROE 3-yr growth
BFBIO — — — — 12.7% —
GLAXO Rs 107.1 bn 10.3× 3.11× 5.1% 32.4% 16.3%
ABOT Rs 97.9 bn 11.4× 3.05× 4.0% 28.8% 15.2%
HALEON Rs 81.6 bn 12.4× 5.02× 4.3% 47.6% 16.2%
HINOON Rs 50.8 bn 12.8× 3.95× 5.2% 32.3% 20.5%
AGP Rs 43.8 bn 11.7× 2.92× 5.1% 25.9% 26.0%
HPL Rs 38.5 bn 10.3× 4.50× 6.0% 38.6% 18.6%
FEROZ Rs 15.8 bn 16.1× 1.19× 1.5% 7.6% 27.9%
CPHL Rs 14.5 bn 18.3× 1.34× 0.0% 7.3% 4.3%

All Pharmaceuticals companies, medians and leaders →

Analyses & signals 0

Win rate — · 0 closed signals · average return —

No analyses published for BFBIO yet.

BFBIO: frequently asked questions

How has BFBIO's share price performed?

BFBIO's share price is down 3.7% year to date (KSE-100: +2.2%) and down 10.8% over one year (KSE-100: +10.7%), as of 13 Nov 2026. These are price returns; dividends are not included.

Information only, not investment advice.